50,000 Shares in GeneDx Holdings Corp. $WGS Bought by Impax Asset Management Group plc

Impax Asset Management Group plc purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $5,387,000. Impax Asset Management Group plc owned approximately 0.17% of GeneDx as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. William Blair Investment Management LLC grew its position in shares of GeneDx by 37.2% during the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock worth $150,595,000 after purchasing an additional 442,414 shares in the last quarter. Jennison Associates LLC boosted its stake in GeneDx by 6,163.1% in the 2nd quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock worth $36,730,000 after purchasing an additional 391,543 shares during the period. Westfield Capital Management Co. LP raised its position in shares of GeneDx by 164.8% during the second quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company’s stock valued at $54,388,000 after buying an additional 366,711 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of GeneDx in the third quarter worth $31,488,000. Finally, Invesco Ltd. boosted its position in shares of GeneDx by 42.3% during the second quarter. Invesco Ltd. now owns 554,419 shares of the company’s stock worth $51,178,000 after acquiring an additional 164,840 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Bryan Dechairo sold 5,961 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total value of $510,857.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Kevin Feeley sold 3,855 shares of GeneDx stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total transaction of $554,618.85. Following the sale, the chief financial officer owned 8,731 shares of the company’s stock, valued at $1,256,128.97. The trade was a 30.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 68,961 shares of company stock worth $10,027,891. Corporate insiders own 29.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on WGS shares. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a research report on Monday. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday. Canaccord Genuity Group raised their price target on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, BTIG Research upped their price objective on GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and an average price target of $138.13.

GeneDx Price Performance

WGS stock opened at $91.44 on Thursday. The stock has a market cap of $2.64 billion, a PE ratio of 1,016.00 and a beta of 2.00. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $170.87. The company has a 50-day moving average price of $122.00 and a 200 day moving average price of $125.15. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.